Descriptive analysis of durvalumab use in unresectable stage III non-small cell lung cancer in patients treated in Quebec’s University teaching hospitals

Authors

Catherine Labbé (ORCID: https://orcid.org/0000-0001-5675-8214)
Mandy Malick (ORCID: https://orcid.org/0009-0003-3571-7060)
Serge Simard
Nicole Bouchard (ORCID: https://orcid.org/0000-0002-5222-6904)
V. Labrie (ORCID: https://orcid.org/0000-0002-8851-0093)
Jean Louis Lefèbvre
Kevin Jao

Institutions

Centre Hospitalier Universitaire de Sherbrooke (CA)
Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean (CA)
Institut universitaire de cardiologie et de pneumologie de Québec (CA)
Hôpital du Sacré-Cœur de Montréal (CA)
Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal (CA)
Université de Montréal (CA)

Publication Details

Journal: Frontiers in Oncology
Published: 2024-12-12
DOI: https://doi.org/10.3389/fonc.2024.1506172
Citations: 2
Primary Topic: Lung Cancer Diagnosis and Treatment
Type: article
Field-Weighted Citation Impact: 0.84

Funders

AstraZeneca

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Descriptive analysis of durvalumab use in unresectable stage III non-small cell lung cancer in patients treated in Quebec’s University teaching hospitals

Catherine Labbé, Mandy Malick, Serge Simard, Nicole Bouchard et al.

Dec 12, 2024

2 citations

Frontiers in Oncology

Lung Cancer Diagnosis and Treatment

0.84

article

Descriptive analysis of durvalumab use in unresectable stage III non-small cell lung cancer in patients treated in Quebec’s University teaching hospitals

Catherine Labbé, Mandy Malick, Serge Simard, Nicole Bouchard, V. Labrie, Jean Louis Lefèbvre, Kevin Jao

December 12, 2024article en

2 citations

Abstract

No abstract available for this paper.

Frontiers in OncologyVol. 14

Centre Hospitalier Universitaire de Sherbrooke (CA), Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean (CA), Institut universitaire de cardiologie et de pneumologie de Québec (CA), Hôpital du Sacré-Cœur de Montréal (CA), Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal (CA), Université de Montréal (CA)

AstraZeneca

Good health and well-being

Openalex Percentile: Top 22%

Lung Cancer Diagnosis and Treatment

0.84

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Descriptive analysis of durvalumab use in unresectable stage III non-small cell lung cancer in patients treated in Quebec’s University teaching hospitals — Catherine Labbé, Mandy Malick, et al. · Frontiers in Oncology (2024) | TGRS Research Map | TGRS